Neo Ivy Capital Management Acquires New Shares in BioCryst Pharmaceuticals, Inc. $BCRX

Neo Ivy Capital Management bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 90,364 shares of the biotechnology company’s stock, valued at approximately $810,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $32,000. New Age Alpha Advisors LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter worth approximately $62,000. Family Legacy Financial Solutions LLC bought a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $72,000. R Squared Ltd boosted its position in BioCryst Pharmaceuticals by 84.2% in the first quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 5,335 shares in the last quarter. Finally, Allianz Asset Management GmbH boosted its position in BioCryst Pharmaceuticals by 9.6% in the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 1,200 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 0.9%

Shares of BCRX stock opened at $6.97 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -38.72 and a beta of 1.09. The stock has a 50-day moving average of $7.22 and a 200-day moving average of $8.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $159.40 million during the quarter, compared to analyst estimates of $162.91 million. BioCryst Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.07) EPS. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

BCRX has been the subject of several research analyst reports. Cantor Fitzgerald upped their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 15th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Barclays cut their price target on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 4th. Finally, Evercore ISI reaffirmed an “in-line” rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.